Partnering
Theraclone collaborates with strategic development partners to create therapeutically important antibody products. We are actively seeking partners in the U.S., Europe, and Japan to help us develop and commercialize therapeutics in the setting of infectious disease and inflammation. Strategic partnerships can be structured on the basis of disease area(s), collaboration roles, degree of financial risk-sharing, and commercial territory. We welcome your inquiries.
Novel human antibodies to pathogenic agents will increase the number of therapeutic options for physicians in acute care settings. We intend to develop anti-infective mAbs derived from vaccinated and immune patients for use in acute care disease settings and in the context of response to pandemic and bioterror challenges.
For vaccine developers, the I-STAR technology can be adapted to assess patients' immune response to new vaccines in the early stages of clinical testing. Comprehensive analysis of the B cell repertoire — including epitope mapping — can be conducted now.
For more information on specific programs, please contact:
David Fanning
President and Chief Executive Officer
Tel: 206-805-1603
Email: dfanning@theraclone-sciences.com